Uncategorized

[VectorY Therapeutics] VectorY Therapeutics announced that the first participant has been dosed in its Phase 1/2 PIONEER-ALS trial evaluating VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in people with ALS.

[Nature Cell Biology] Investigators used live-cell microscopy to examine the impact of Parkinson’s disease associated lipid alterations on α-synuclein release. They discovered that increased glucosylceramides as a consequence of reduced β-glucocerebrosidase activity induce ectosome shedding from primary neurons.

[Science Advances] Using Parkinson’s disease patient-derived and CRISPR-engineered iPSC midbrain dopaminergic neurons lacking DJ-1, researchers identified defective sequestration of cytosolic dopamine into synaptic vesicles.

[Cell Death & Disease] Scientists demonstrated that heat shock protein family A member 5 (HSPA5) expression was highest in the mesenchymal subtype of glioblastoma. The overexpression of HSPA5 in proneural cells induced proneural-to-mesenchymal transition and promoted malignant phenotypes.

[Cell Death & Disease] Researchers demonstrated that the injection of mitochondrial DNA into the substantia nigra pars compacta induces Parkinson’s disease pathology in mice, characterized by the loss of dopaminergic neurons and the activation of microglia.

[Journal of Translational Medicine] The authors investigated the upstream regulatory mechanisms of N-Myc stabilization in neuroblastoma and explored potential therapeutic strategies targeting these mechanisms.

[Journal of Medicinal Chemistry] Investigators established paroxetine as a functional heat shock protein 27 (HSP27) inhibitor that disrupts the interaction between HSP27 and MMP-2/9, thereby inhibiting glioblastoma progression.

[Scientific Reports] Researchers found that Wnt-3a alone had no effect on pro-inflammatory TNF-α or IL-1β release from homeostatic primary microglia, however co-administration with LPS significantly increased TNF-α release beyond that seen with LPS alone.

[Journal of Biomedical Science] Scientists provide a comprehensive introduction to the structure, neurotoxicity, regulatory mechanism, and relevance of APP-C31 to clinical diseases and its therapeutic potential as a drug target.

[Experimental & Molecular Medicine] Investigators highlight advances in modeling MS progression, using human induced pluripotent stem cell-derived systems, with a particular focus on microglia as key mediators of neuroinflammation and neurodegeneration.

[Discover Oncology] The authors summarize resistance-associated changes across three key areas – glycolysis, redox homeostasis, and lipid metabolism in temozolomide-resistant glioblastoma.

[Biomacromolecules] Investigators demonstrated the construction of poly(ethylene glycol)-derived hydrogels by efficient cross-linking of quinolinium acyltrifluoroborate-functionalized macromers with a partner hydroxylamine-functionalized macromer.